Mammalian muscle cell differentiation is a complex process of multiple steps for which many of the factors involved have not yet been defined. In a screen to identify the regulators of myogenic cell fusion, we found that the G-protein coupled receptor 56 (GPR56) gene was transiently upregulated during the early fusion of human myoblasts. Human mutations in GPR56 cause the disease bilateral frontoparietal polymicrogyria (BFPP), however the consequences of receptor dysfunction on muscle development have not been explored. Using knockout mice, we defined the role of GPR56 in skeletal muscle. GPR56−/− myoblasts have decreased fusion and smaller myotube sizes in culture. In addition, loss of GPR56 expression in muscle cells results in decreases or delays in the expression of MyoD, myogenin, and NFATc2. Our data suggest that these abnormalities result from decreased GPR56-mediated SRE and NFAT signaling. Despite these changes, no overt differences in phenotype were identified in the muscle of GPR56 knockout mice, which presented only a mild but statistically significant elevation of serum creatine kinase (CK) compared to wildtype. In agreement with these findings, clinical data from 13 BFPP patients revealed mild serum CK increase in only 2 patients. In summary, targeted disruption of GPR56 in mice results in myoblast abnormalities. The absence of a severe muscle phenotype in GPR56 knockout mice and human patients suggests that other factors may compensate for the lack of this GPCR during muscle development and that the motor delay observed in these patients is likely not due to primary muscle abnormalities.